

Distinct In Vitro Properties of Embryonic and Extraembryonic  
Fibroblast-Like Cells Are Reflected in Their In Vivo Behavior Following  
Grafting in the Adult Mouse Brain

Peer-reviewed author version

Costa, Roberta; Bergwerf, Irene; SANTERMANS, Eva; De Vocht, Nathalie; Praet, Jelle; Daans, Jasmijn; Le Blon, Debbie; Hoomaert, Chloe; Reekmans, Kristien; HENS, Niel; Goossens, Herman; Berneman, Zwi; Parolini, Ornella; Alviano, Francesco & Ponsaerts, Peter (2015) Distinct In Vitro Properties of Embryonic and Extraembryonic Fibroblast-Like Cells Are Reflected in Their In Vivo Behavior Following Grafting in the Adult Mouse Brain. In: CELL TRANSPLANTATION, 24 (2), p. 223-233.

DOI: 10.3727/096368913X676196

Handle: <http://hdl.handle.net/1942/18719>

**Distinct in vitro properties of embryonic and extra-embryonic fibroblast-like cells are reflected in their in vivo behaviour following grafting in the adult mouse brain.**

Journal:	<i>Cell Transplantation</i>
Manuscript ID:	CT-1128.R1
Manuscript Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Costa, Roberta Bergwerf, Irene Santermans, Eva De Vocht, Nathalie Praet, Jelle Daans, Jasmijn Le Blon, Debbie Hoornaert, Chloé Reekmans, Kristien Hens, Niel Goossens, Herman Berneman, Zwi; University of Antwerp, Experimental Hematology Parolini, Ornella Alviano, Francesco Ponsaerts, Peter; University of Antwerp, Experimental Hematology
Keywords:	Foetal membrane-derived stromal cells, embryonic fibroblasts, immunomodulation, transplantation, angiogenesis
Abstract:	Although intracerebral transplantation of various fibroblast(-like) cell populations has been shown feasible, little is known about the actual in vivo remodelling of these cellular grafts and their environment. In this study, we aimed to compare the in vitro and in vivo behaviour of two phenotypically similar - but developmentally distinct - fibroblast-like cell populations, namely mouse embryonic fibroblasts (mEF) and mouse foetal membrane-derived stromal cells (mFMSC). While both mEF and mFMSC are readily able to reduce TNF $\alpha$ secretion by LPS/IFN $\gamma$ -activated BV2 microglia, mFMSC and mEF display a strikingly opposite behaviour with regard to VEGF production under normal and inflammatory conditions. Whereas mFMSC downregulate VEGF production upon co-culture with LPS/IFN $\gamma$ -activated BV2 microglia, mEF upregulate VEGF production in the presence of LPS/IFN $\gamma$ -activated BV2 microglia. Subsequently, in vivo grafting of mFMSC and mEF revealed no difference in microglial and astroglial responses towards the cellular grafts. However, mFMSC grafts displayed a lower degree of neo-angiogenesis as compared to mEF grafts, thereby potentially explaining the lower cell number able to survive in mFMSC grafts. In summary, our results suggest that physiological

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	differences between fibroblast-like cell populations might lie at the basis of variations in histopathological and/or clinical outcome following cell grafting in mouse brain.

SCHOLARONE™  
Manuscripts

For Review Only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Distinct in vitro properties of embryonic and extra-embryonic fibroblast-like cells are reflected in their in vivo behaviour following grafting in the adult mouse brain.**

Roberta Costa<sup>1</sup>, Irene Bergwerf<sup>2,3</sup>, Eva Santermans<sup>4</sup>, Nathalie De Vocht<sup>2,3</sup>, Jelle Praet<sup>2,3</sup>, Jasmijn Daans<sup>2,3</sup>, Debbie Le Blon<sup>2,3</sup>, Chloé Hoornaert<sup>2,3</sup>, Kristien Reekmans<sup>2,3</sup>, Niel Hens<sup>4,5</sup>, Herman Goossens<sup>3</sup>, Zwi Berneman<sup>2,3</sup>, Ornella Parolini<sup>6</sup>, Francesco Alviano<sup>1</sup> and Peter Ponsaerts<sup>2,3</sup>

<sup>1</sup> Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

<sup>2</sup> Experimental Cell Transplantation Group, Laboratory of Experimental Hematology, University of Antwerp, Antwerp, Belgium.

<sup>3</sup> Vaccine and Infectious Disease Institute (Vaxinfectio), University of Antwerp, Antwerp, Belgium.

<sup>4</sup> Center for Statistics, I-Biostat, Hasselt University, Hasselt, Belgium.

<sup>5</sup> Centre for Health Economic Research and Modeling Infectious Diseases (Chermid), University of Antwerp, Antwerp, Belgium.

<sup>6</sup> Centro di Ricerca E. Menni, Fondazione Poliambulanza – Istituto Ospedaliero, Brescia, Italy.

**Running head:** differential in vivo behaviour of cellular grafts

**Corresponding author:**

prof. dr. Peter Ponsaerts, Experimental Cell Transplantation Group, Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (Vaxinfectio), University of Antwerp, Campus Drie Eiken (CDE-S6.51), Universiteitsplein 1, 2610 Antwerp (Wilrijk), Belgium. Tel.: 0032-3-2652428 - E-mail: [peter.ponsaerts@uantwerpen.be](mailto:peter.ponsaerts@uantwerpen.be)

**Abstract:**

Although intracerebral transplantation of various fibroblast(-like) cell populations has been shown feasible, little is known about the actual *in vivo* remodelling of these cellular grafts and their environment. In this study, we aimed to compare the *in vitro* and *in vivo* behaviour of two phenotypically similar - but developmentally distinct - fibroblast-like cell populations, namely mouse embryonic fibroblasts (mEF) and mouse foetal membrane-derived stromal cells (mFMSC). While both mEF and mFMSC are readily able to reduce TNF $\alpha$  secretion by LPS/IFN $\gamma$ -activated BV2 microglia, mFMSC and mEF display a strikingly opposite behaviour with regard to VEGF production under normal and inflammatory conditions. Whereas mFMSC downregulate VEGF production upon co-culture with LPS/IFN $\gamma$ -activated BV2 microglia, mEF upregulate VEGF production in the presence of LPS/IFN $\gamma$ -activated BV2 microglia. Subsequently, *in vivo* grafting of mFMSC and mEF revealed no difference in microglial and astroglial responses towards the cellular grafts. However, mFMSC grafts displayed a lower degree of neo-angiogenesis as compared to mEF grafts, thereby potentially explaining the lower cell number able to survive in mFMSC grafts. In summary, our results suggest that physiological differences between fibroblast-like cell populations might lie at the basis of variations in histopathological and/or clinical outcome following cell grafting in mouse brain.

**Key words:**

Foetal membrane-derived stromal cells, embryonic fibroblasts, immunomodulation, transplantation, brain, angiogenesis

## INTRODUCTION

Transplantation of fibroblastic cells, including adult/embryonic fibroblasts and mesenchymal stromal cells, is widely being applied in various preclinical animal models of human disease. Major interest into these cell populations can be explained by the relatively easy *in vitro* isolation (and/or expansion) protocols and the exceptional immune-modulating and regeneration-inducing properties of these cells (2). However, while extensive *in vitro* experiments have shed light on potential working mechanisms for the improved clinical outcome following fibroblastic cell grafting in several disease models, including those of the central nervous system (CNS), currently little is known about the actual *in vivo* behaviour of these cellular grafts (1,7). In our preceding studies, we contributed to a better understanding of the cellular events following syngeneic reporter gene-modified murine bone marrow-derived mesenchymal stromal cell (mMSC) and murine embryonic fibroblast (mEF) grafting in the healthy and injured CNS of immune-competent mice (4,5,10,21). In course of these studies, it was noted that both mMSC and mEF grafting in the CNS, independent of a preceding injury, results in the activation of strong microglial and astroglial cell responses. Without manifest differences, both mMSC and mEF grafts become highly surrounded and infiltrated with Iba1+ microglia(/macrophages). In addition, both mMSC and mEF grafts become surrounded, but not infiltrated, by highly activated GFAP+ astrocytes. Given the *in vivo* occurrence of cellular immune responses against grafted fibroblastic cells, although we do not yet know the exact mechanism behind, further research towards identifying a cell population that triggers no or minimal CNS immune responses upon transplantation is highly desirable. The latter will not only lead to the application of safer therapeutic cell-based therapies, but more importantly, might lead to the establishment of therapeutic interventions in which functional cell integration might occur in the adult immune competent CNS (5).

Recently, the placenta, foetal membranes and amniotic fluid have been put forward as alternative

1  
2  
3  
4 sources for cells of mesenchymal origin in cell transplantation experiments (16,29). Based on the  
5  
6 observation that during pregnancy the competent immune system of the mother is rendered tolerant to  
7  
8 the immunologically distinct foetus, the placenta and foetal membranes, which are the interface  
9  
10 between mother and foetus, may harbour these immune regulating properties. The hypothesis that  
11  
12 foetal membranes are a non immunogenic tissue has been confirmed by several clinical studies that  
13  
14 used amniotic membranes for treatment of skin wounds, dermal burns, non-healing ulcers, ocular  
15  
16 surface reconstruction, or to prevent tissue adhesion in surgical procedures (12,16). In these clinical  
17  
18 studies, no immune-mediated rejection was observed in the absence of immune suppressive treatment.  
19  
20 Moreover, fibroblast-like cells isolated from foetal membranes, generally termed foetal membrane-  
21  
22 derived stromal cells (FMSC), can present the same immunological behaviour. In this context, several  
23  
24 preclinical studies in animal models of disease demonstrated that transplantation of human (h)FMSC  
25  
26 significantly contributes to anti-inflammatory and anti-scarring processes rather than actual cell  
27  
28 replacement. For example, hFMSC transplantation for the treatment of liver and lung fibrosis in  
29  
30 rodents showed a reduction in neutrophil infiltration and in the dimension of the fibrotic lesion (8,17).  
31  
32 This immunological behaviour of hFMSC has also been observed following neural injury.  
33  
34 Transplantation of hFMSC after stroke in rodents has shown to reduce injury progression by  
35  
36 modulating the inflammatory response and facilitating functional recovery (16,19). Furthermore, other  
37  
38 *in vivo* experiments have demonstrated long-term survival of hFMSC after xenogeneic transplantation  
39  
40 into immune competent animals (12,14).  
41  
42  
43  
44  
45  
46  
47

48 However, despite demonstrating significant immune modulating effects, the xenogeneic  
49  
50 transplantation of human cells into rodents has significant limitations when aiming to translate the  
51  
52 observed clinical benefits to human clinical applications that will be performed with autologous or  
53  
54 allogeneic cell grafts. Therefore, in this novel study we first optimised an isolation procedure for  
55  
56 murine (m)FMSC and characterised the resulting mFMSC population *in vitro* and *in vivo* following  
57  
58  
59  
60

1  
2  
3  
4 syngeneic grafting in the CNS. Comparing the obtained data with a mEF control cell population, this  
5  
6 study describes functional differences between fibroblast-like cell populations isolated from different  
7  
8 tissues, both *in vitro* and *in vivo* upon grafting in the CNS.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Review Only



## **MATERIALS AND METHODS**

### ***Animals***

Female wild type C57BL/6 mice (Charles River Laboratories, strain code 027) were crossed with male transgenic C57BL/6-eGFP mice (Jackson Laboratories, strain code 003291) and both eGFP<sup>+</sup> and eGFP<sup>-</sup> embryos/foetal membranes were used for cell isolation experiments. Male wild type C57BL/6 mice (Charles River Laboratories, strain code 027), 8-9 weeks of age, were used for cell implantation experiments (n=10). For all experiments, mice were kept under normal day-night cycle (12-12) with free access to water and food. All experimental procedures were approved by the ethical committee for animal experiments of the University of Antwerp (approval n. 2011-13).

### ***Cell culture***

mFMSC were isolated from eGFP<sup>+</sup> and eGFP<sup>-</sup> foetal membranes surrounding respectively eGFP<sup>+</sup> and eGFP<sup>-</sup> embryos following crossing of female wild type C57BL/6 mice with male transgenic C57BL/6-eGFP mice. For this, embryos (E17-18) were removed from the uterus and each foetal membrane was separated manually from the placenta and the embryo. Foetal membranes were recovered, washed with PBS (Gibco) and enzymatically digested by the following consecutive dissociation steps: 3 minutes in PBS supplemented with Dispase (2.5 U/ml, Gibco), 3 hours in RPMI medium (Gibco) supplemented with Collagenase A (1.5 mg/ml, Roche) and DNase I (0.002 mg/ml, Sigma), and 3 minutes in 0.05% Trypsin-EDTA (Invitrogen). The cell suspension obtained was then plated in 6 well plates (Corning) at a cell density of  $7-9 \times 10^4$  cells/cm<sup>2</sup> (one well for each foetal membrane) in RPMI medium supplemented with 10% foetal calf serum (FCS, Hyclone), 100 U/ml Penicillin (Invitrogen) and 100 mg/ml Streptomycin (Invitrogen). For cell expansion and to establish a growth curve, cell culture medium was replaced every 3 days and cells were split 1:2 and counted every 4 days. mEF were cultured from eGFP<sup>+</sup> and eGFP<sup>-</sup> embryos following crossing of female wild

1  
2  
3  
4 type C57BL/6 mice with male transgenic C57BL/6-eGFP mice, according to previously described  
5 procedures (21). For cell expansion, mEF medium (DMEM (with 4.5 g/L glucose and L-glutamine,  
6 Gibco) supplemented with 10% FCS, 100 U/ml Penicillin and 100mg/ml Streptomycin) was replaced  
7 every 2-3 days and cells were split 1:3 every 4-5 days. In order to establish a growth curve, mEF  
8 cultures were plated at  $9 \times 10^4$  cells/cm<sup>2</sup>, split 1:2 and counted every 4 days. BV2 microglial cells  
9 (kindly provided by prof. R. Donato, University of Perugia, Italy) were cultured in DMEM  
10 supplemented with 10% FCS, 100 U/ml Penicillin and 100mg/ml Streptomycin. For cell culture, BV2  
11 medium was replaced every 2 days and cells were split 1:5 every 3 days. All cell cultures were  
12 incubated in a humidified incubator at 37°C with 5% CO<sub>2</sub>.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

### 26 *Flow cytometric analysis*

27  
28 Immunophenotyping of eGFP- mFMSC and eGFP- mEF cell populations was performed using the  
29 following directly labelled antibodies: phycoerythrin (PE)-labelled rat anti mouse Sca1 (R&D,  
30 FAB1226P), PE-labelled mouse anti mouse CD90 (eBioscience, 12-0900-81), PE-labelled rat anti  
31 mouse CD44 (eBioscience, 12-0441-81), PE-labelled rat anti mouse MHC class II (eBioscience, 12-  
32 5321-82), PE-labelled rat anti mouse CD184 (BD, 551966), PE-labelled mouse anti mouse H2Kb (BD  
33 553570), fluorescein (FITC)-labelled rat anti mouse CD45 (eBioscience 11-0451-82), FITC-labelled  
34 rat anti mouse CD106 (eBioscience, 11-1061-82), FITC-labelled rat anti mouse CD31 (eBioscience,  
35 11-0311-82), FITC-labelled rat anti mouse CD4 (eBioscience, 11-0041-82), FITC-labelled rat anti  
36 mouse CD8a (eBioscience, 11-0081-82), FITC-labelled rabbit anti mouse TGFβ RII (Santa Cruz, sc-  
37 1700). **Before staining, harvested cells were washed twice with PBS and suspended in PBS at a  
38 concentration of  $2 \times 10^6$  cells/ml. For antibody staining, 1 μg of antibody was added to 100 μl of cell  
39 suspension for 30 min at 4°C. Following incubation, cells were washed once with PBS, suspended in 1  
40 mL PBS, and analysed by flow cytometry. For detection of eGFP transgene expression, harvested  
41 eGFP+ mFMSC and eGFP+ mEF were washed once with PBS, suspended in PBS and directly**  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 analysed by flow cytometry. For all analyses, cell viability was assessed by adding GelRed (1× final  
5 concentration, Biotum) to the cell suspension immediately before flow cytometric analysis. All flow  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

analysed by flow cytometry. For all analyses, cell viability was assessed by adding GelRed (1× final concentration, Biotum) to the cell suspension immediately before flow cytometric analysis. All flow cytometric analyses were performed using an Epics XL-MCL analytical flow cytometer (Beckman Coulter) and all data were analysed using FlowJo flow cytometry data analysis software (FlowJo).

### *Cell differentiation assays*

For adipogenic differentiation, mFMSC and mEF were plated at  $2 \times 10^4$  cells/cm<sup>2</sup> in 24 well plates (Corning) followed by culture in Mesenchymal Stem Cell Adipogenic Differentiation Medium (PT 3004, Lonza), according to the manufacturer's instructions. Control non-induced cells were kept in basal medium (RPMI 10% FCS for mFMSC and DMEM 10% FCS for mEF). After 3 weeks of culture, cells were fixed with 4% paraformaldehyde and stained with fresh Oil Red O solution (Sigma). For osteogenic differentiation, mFMSC and mEF were plated at  $1 \times 10^4$  cells/cm<sup>2</sup> in 24 well plates followed by culture in Mesenchymal Stem Cell Osteogenic Differentiation Medium (PT 3002, Lonza), according to the manufacturer's instructions. Control non-induced cells were kept in basal medium. After 3 weeks of culture, cells were fixed with 4% paraformaldehyde (Sigma) and stained with Alizarin Red S (Sigma). For chondrogenic differentiation,  $2.5 \times 10^5$  mFMSC or mEF were pelleted in 15 ml conical tubes (Greiner) followed by culture in Mesenchymal Stem Cell Chondrocyte Differentiation Medium (PT 3003, Lonza) supplemented with TGFβ 3 (Sigma), according to the manufacturer's instructions. Control non-induced cells were kept in basal medium after pelleting. After 3 weeks of induction, cells were fixed with 4% paraformaldehyde and stained with Alcian Blue (Sigma).

### *mFMSC and mEF co-culture experiments with BV2 cells*

mFMSC and mEF were plated at a concentration of  $5 \times 10^4$  cells/well in a 24 well plate and allowed to adhere during overnight incubation. Next, in order to assess the effect of mFMSC and mEF on BV2

1  
2  
3  
4 microglial cells,  $1 \times 10^5$  BV2 cells were plated onto the confluent layer of mFMSC or mEF. Following  
5  
6 24 hours of co-culture, cultures were additionally stimulated with lipopolysaccharide (LPS, Invivogen,  
7  
8  $1 \mu\text{g/ml}$ ) + interferon- $\gamma$  (IFN $\gamma$ ) (R&D Systems, 500U/ml) to assess the effect of mFMSC and mEF on  
9  
10 activated BV2 microglial cell (28). After an additional 24 hours of stimulation (or under control  
11  
12 conditions) supernatants was harvested and analysed for the presence of TNF $\alpha$  and VEGF by means  
13  
14 of ELISA, according to the manufacturer's instructions (murine TNF $\alpha$  ELISA from Biologend, murine  
15  
16 VEGF ELISA from Peprotech).  
17  
18  
19

### 20 21 22 ***Cell implantation experiments*** 23

24 Cell implantation in the CNS of immune competent mice was performed under sterile conditions  
25  
26 according to previously established procedures (10,21,24). Briefly, eGFP-expressing mFMSC and  
27  
28 mEF were harvested, washed with PBS and resuspended at a concentration of approximately  $41.6 \times 10^6$   
29  
30 cells / ml in PBS. Directly prior to and post transplantation, the cell number was recounted in order to  
31  
32 control for the actual number of injected cells ( $5 \times 10^4$  cells in  $1.2 \mu\text{l}$  PBS). For cell implantation, mice  
33  
34 were anesthetized by an intraperitoneal injection of a ketamin (80 mg/kg, Pfizer) + xylazin (16 mg/kg,  
35  
36 Bayer Health care) mixture in PBS and placed in a stereotactic frame (Stoelting). Next, a midline scalp  
37  
38 incision was made and a hole was drilled in the skull using a dental drill burr (Stoelting) at the  
39  
40 following coordinates relative to bregma: 0.5 mm posterior and 2.2 mm lateral to the right side of the  
41  
42 midline. Thereafter, an automatic microinjector pump (kdScientific) with a  $10\text{-}\mu\text{l}$  Hamilton syringe  
43  
44 was positioned above the exposed dura. A 30-gauge needle (Hamilton), attached to the syringe, was  
45  
46 stereotactically placed through the intact dura to a depth of 3.3 mm. After 2 min of pressure  
47  
48 equilibration,  $5 \times 10^4$  cells of the respective populations were injected in a volume of  $1.2 \mu\text{l}$  PBS at a  
49  
50 speed of  $0.7 \mu\text{l/min}$ . The needle was retracted after another 4 min to allow pressure equilibration and  
51  
52 to prevent backflow of the injected cell suspension. Next, the skin was sutured (Vicryl, Ethicon) and a  
53  
54  
55  
56  
57  
58  
59  
60

0.9% NaCl solution (Baxter) was administered subcutaneously in order to prevent dehydration while mice were placed under a heating lamp to recover.

### ***Histological analysis – immunofluorescence staining***

Preparation of brain tissue for histological examination was performed according to previously optimised procedures (10,21,22). Serial 10- $\mu$ m thick cryosections were obtained from the entire implant region using a Microm HM5000 cryostat (Prosan), consecutively marked and missing slides were noted. For further immunofluorescence analysis of tissue sections, antibody staining was performed as previously described (10,21,22) using the following antibodies: (i) a rabbit anti-mouse Iba1 antibody (Wako 019-19741, 1/400 dilution) in combination with an Alexa Fluor® 555-labelled donkey anti-rabbit secondary antibody (Invitrogen A31572, 1/1000 dilution), (ii) a mouse anti-mouse GFAP antibody (Millipore mab377, 1/400 dilution) in combination with an Alexa Fluor® 350-labelled goat anti-mouse secondary antibody (Invitrogen A11068, 1/200 dilution), (iii) a rabbit anti-mouse S100b antibody (Abcam ab52642, 1/400 dilution) in combination with an Alexa Fluor® 555-labelled donkey anti-rabbit secondary antibody (Invitrogen A-31572, 1/1000 dilution), (iv) a rabbit anti-mouse CD31 antibody (Abcam AB28364, 1/50 dilution) in combination with a Texas Red-labelled goat anti-rabbit secondary antibody (Abcam AB6719, 1/1000 dilution). Antibody stainings were performed using the following single or double staining combinations: (i) Iba1 (n = 2 per cell grafted mouse brain), (ii) S100b + GFAP (n = 2 per cell grafted mouse brain), (iii) CD31 (n = 1 per cell grafted mouse brain). In brief, slides were rinsed for 5 min in Tris-buffered saline (TBS) and subsequently incubated for 30 min in 0.1% Triton-X (Merck) in TBS. Next, slides were washed, followed by a 1 hour incubation at room temperature in TBS + blocking serum (for Iba-1 staining TBS + 20% donkey serum from Jackson ImmunoResearch (017-000-121); for S100b/GFAP staining TBS + 20% donkey serum, 20% goat serum from Jackson ImmunoResearch (005-000-121) and 1% unconjugated goat anti-mouse Ig from Jackson ImmunoResearch (115-007-003 ); for CD31 staining TBS + 20% goat

1  
2  
3  
4 serum). Next, blocking solution was removed and slides were incubated overnight at 4°C with the  
5  
6 primary antibodies diluted in TBS + 10% (w/v) milk powder. Next, slides were washed with TBS (4 x  
7  
8 3 min) and incubated for 1 h at room temperature on a horizontal shaker (at 60 rpm) with the  
9  
10 secondary antibodies diluted in TBS + 10% (w/v) milk powder. Thereafter, slides were washed with  
11  
12 TBS (4 x 3 min) and a 20 min nuclear staining was performed using Topro-3 (Invitrogen, T3605,  
13  
14 1/200 dilution). Following final washing with TBS (3 x 2 min), stained slides were mounted using  
15  
16 Prolong Gold Antifade Reagent (Invitrogen, P36930) and images were acquired using an Olympus  
17  
18 BX51 microscope equipped with an Olympus DP71 digital camera. Olympus CellSense software was  
19  
20 used for image acquisition.  
21  
22  
23  
24  
25

### 26 ***Histological analysis – quantitative analysis***

27  
28 Quantitative analysis of cell graft survival, glial cell responses and angiogenesis was performed using  
29  
30 NIH ImageJ analysis software (ImageJ) and TissueQuest immunofluorescence analysis software  
31  
32 (TissueGnostics GmbH) as previously described (10,22), allowing determination of the following  
33  
34 parameters: (i) the mFMSC/mEF graft site volume in mm<sup>3</sup> (1 data count per cell graft analysed), (ii)  
35  
36 the density (in cells/mm<sup>3</sup>) and absolute number of eGFP+ mFMSC/mEF within the graft site (4  
37  
38 estimates per cell graft analysed), (iii) the mFMSC/mEF cell graft survival provided in absolute  
39  
40 numbers and in % calculated to the initial number of grafted eGFP+ viable mFMSC/mEF (4 estimates  
41  
42 per cell graft analysed), (iv) the density (in cells/mm<sup>3</sup>) and absolute number of Iba1+ microglia within  
43  
44 the mFMSC/mEF graft site (4 estimates per cell graft analysed), (v) the density (in cells/mm<sup>3</sup>) of  
45  
46 Iba1+ microglia within the mFMSC/mEF graft site border, as determined by a region extending 100  
47  
48 µm from the mFMSC/mEF graft site (2 estimates per cell graft analysed), (vi) the density (in  
49  
50 cells/mm<sup>3</sup>) of S100b+ astrocytes within the mFMSC/mEF graft site border (2 estimates per cell graft  
51  
52 analysed), (vii) the degree of GFAP+ astrogliosis within the mFMSC/mEF graft site border provided  
53  
54 as % astrogliosis (2 estimates per cell graft analysed), and (viii) the density (in cells/mm<sup>2</sup>) of CD31+  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 blood vessels within the mFMSC/mEF graft (one data count per cell graft analysed).  
5  
6  
7

### 8 9 *Statistical analyses*

10 All statistical analyses were performed using the IBM SPSS version 20 statistical package. To  
11 examine differences in *in vitro* cell growth (day 0, day 4 and day 8 post-plating) between mFMSC and  
12 mEF cultures, a mixed model with repeated measures and a first-order autoregressive covariance  
13 structure was fitted. To evaluate differences in *in vitro* TNF- $\alpha$ /VEGF secretion, both outcomes were  
14 first transformed using an inverse-logistic equation. A one-way ANOVA was then performed on these  
15 transformed variables and several post-hoc tests were used to assess statistically significant differences  
16 (highest p-value is reported). To evaluate differences in graft site volume, total cell number within the  
17 graft site, number of eGFP+ cells within the graft site, % cell graft survival, ratio microglia vs. eGFP+  
18 cells within the graft site, density of microglia in the graft site surrounding, density of astrocytes in the  
19 graft site surrounding, % of astrogliosis and density of blood vessels within the graft site, Generalized  
20 Estimating Equations (30) taking into account repeated measures were used. This method does not  
21 require a priori specification of the association structure. The obtained p-values were corrected using  
22 the false-discovery rate control (3). For all comparisons, a p-value < 0.05 was considered to be  
23 statistically significant.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## RESULTS

### *Phenotypical characterisation of mFMSC and mEF cultures*

mFMSC and mEF were isolated from wild-type C57BL/6 mice or from transgenic C57BL/6-eGFP mice, as described in the materials and methods section. As shown in figure 1A (a+b, main images), both mFMSC and mEF are adherently cultured cell populations displaying a typical fibroblast-like morphology. When mFMSC-eGFP and mEF-eGFP were isolated from C57BL/6-eGFP transgenic mice, both cell populations uniformly displayed high eGFP expression as measured by flow cytometry (figure 1A, a+b, inset images). Further flow cytometric immunophenotyping of mFMSC and mEF characterised both cell populations as follows: Sca1+, CD44+, CD90+ (low), CD31-, CD106-, CD45-, CD184-, CD4-, CD8-, TGFβR2-, MHC1- and MHC2+ (low) (figure 1A, c+d). Of note, these embryonic stromal cell populations are phenotypically slightly different from adult C57BL/6 murine bone marrow-derived mesenchymal stromal cells (mBMMSC), as the latter were previously characterised as: Sca1+ (high), CD44+ (high), CD90-, CD31-, CD106-, CD45-, CD184-, CD4-, CD8-, TGFβR2-, MHC1+ (low) and MHC2+ (low), **implying small phenotypic variations between fibroblast-like cell types derived from adult or embryonic tissues** (data not shown).

### *Functional characterisation of mFMSC and mEF*

First, we evaluated the proliferative capacity of the isolated mFMSC and mEF cell populations (figure 1B). While mEF cultures can easily be expanded *in vitro* ( $p < 0.001$ ), mFMSC did not display any proliferation. Moreover, in the current setup, we were unable to maintain mFMSC in culture for more than 2-3 weeks due to cell detachment followed by cell death ( $p < 0.001$ ). Next, we evaluated the *in vitro* differentiation potential of mFMSC and mEF. For this, both cell types were cultured in commercially available adipogenic, osteogenic and chondrogenic differentiation media. As shown in



1  
2  
3  
4 figure 1C (left panels), mFMSC displayed a reduced differentiation potential, limited to a low  
5 osteogenic commitment, as compared to mEF, which were able to differentiate to both adipogenic and  
6 osteogenic lineages. No spontaneous adipogenic or osteogenic differentiation was observed for non-  
7 stimulated mFMSC and mEF cultures (figure 1C, right panels). Neither mFMSC nor mEF underwent  
8 chondrogenic differentiation upon culture in chondrogenic differentiation medium (data not shown).  
9  
10  
11  
12  
13  
14  
15  
16  
17

### 18 ***Immunomodulating effect of mFMSC and mEF on BV2 microglia***

19  
20 In this part of the study, we aimed to investigate whether mFMSC or mEF could exert an  
21 immunomodulating effect on the activation of the C57BL/6-derived BV2 microglial cell line. To this  
22 end, we followed the experimental set-up as described in figure 1D (a, upper scheme). As shown in  
23 figure 1D (b, lower graph), BV2 cells readily produce high amounts of TNF $\alpha$  upon stimulation with  
24 LPS/IFN $\gamma$  ( $p < 0.001$  for BV2 vs. BV2+LPS/IFN $\gamma$ ). mFMSC do not produce significant amounts of  
25 TNF $\alpha$ , nor upon stimulation with LPS/IFN $\gamma$  or co-culture with BV2 cells. However, when  
26 mFMSC/BV2 co-cultures are stimulated with LPS/IFN $\gamma$ , a reduced production of TNF $\alpha$  by BV2 cells  
27 can be noted ( $p < 0.001$  for mFMSC+BV2+LPS/IFN $\gamma$  vs. BV2+LPS/IFN $\gamma$ ). While mEF alone or upon  
28 co-culture with BV2 cells do not produce significant amounts of TNF $\alpha$ , stimulation of mEF with  
29 LPS/IFN $\gamma$  leads to a significant increase in TNF $\alpha$  production ( $p < 0.001$  for mEF vs. mEF+LPS/IFN $\gamma$ ).  
30 This observation indicates that, independent of their embryonic fibroblast-like origin, both mFMSC  
31 and mEF behave differently upon encounter of immune stimuli. Nevertheless, even though mEF can  
32 produce significant amounts of TNF $\alpha$ , in the event of LPS/IFN $\gamma$  stimulation of mEF/BV2 co-cultures,  
33 an overall reduced production of TNF $\alpha$  by BV2 (or mEF) cells can be noted ( $p = 0.001$  for  
34 mEF+BV2+LPS/IFN $\gamma$  vs. BV2+LPS/IFN $\gamma$ ). Based on the presented data, we conclude that both  
35 mFMSC and mEF are able to partially modulate *in vitro* activation of the BV2 microglial cell line.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

***Differential production of VEGF by mFMSC and mEF under normal and inflammatory conditions***

In this part of the study, we investigated the *in vitro* secretion of VEGF by mFMSC and mEF cultures in the absence or presence of (activated) BV2 microglial cells (see figure 1D, (a) upper scheme for experimental set-up). As shown in figure 1E, mFMSC cultures secrete significantly higher levels of VEGF in comparison to mEF cultures ( $p < 0.001$  for mFMSC vs. mEF). Unexpectedly, in the presence of (activated) BV2 microglia, mFMSC reduce their production of VEGF ( $p < 0.001$  for mFMSC vs. mFMSC + BV2 and  $p = 0.004$  for mFMSC vs. mFMSC + BV2 + LPS/IFN $\gamma$ ). In contrast, mEF display an increased VEGF production upon application of pro-inflammatory stimuli ( $p < 0.001$  for mEF vs. mEF + LPS/IFN $\gamma$ ), which is further increased by the presence of activated BV2 microglia ( $p < 0.001$  for mEF + LPS/IFN $\gamma$  vs. mEF + BV2 + LPS/IFN $\gamma$ ). Based on the presented data, we conclude that mFMSC and mEF might display different angiogenic properties upon *in vivo* grafting into an inflammatory environment.

***Quantitative analysis of mFMSC and mEF graft survival following intracerebral transplantation***

Next, we aimed to investigate the *in vivo* behaviour of mFMSC and mEF upon autologous grafting in the CNS of immune competent mice. To this end,  $5 \times 10^4$  mFMSC-eGFP or  $5 \times 10^4$  mEF-eGFP were grafted into the CNS of syngeneic C57BL/6 mice ( $n = 5$  for each group). Histological analyses of brain tissue from cell-grafted mice were performed at day 14 post-implantation. For this, cryosections of the whole graft site area were prepared and screened for the presence of eGFP-expressing mFMSC or mEF implants. From the representative images provided in figure 2A, it is clear that eGFP-expressing cellular grafts could be detected 2 weeks after implantation (cell grafts were identified in 4/5 mice transplanted with mFMSC-eGFP and in 5/5 mice transplanted with mEF-eGFP). Notably, the graft site volume (i.e. the volumetric area containing eGFP-expressing cells, figure 2Ba) and the total number of cells within the graft site (comprising both eGFP-expressing grafted cells and microglia, figure 2Bb) is

1  
2  
3  
4 significantly smaller for mFMSC grafts as compared to mEF grafts (respectively  $p<0.001$  and  
5  
6  $p=0.002$ ). Subsequently, it was noted that the number of eGFP+ cells within mFMSC grafts was  
7  
8 significantly lower than the number of eGFP+ cells within mEF grafts (figure 2Bb,  $p<0.001$ ).  
9  
10 Comparing with the initial number of grafted cells ( $5 \times 10^4$  cells), a significantly different degree of cell  
11  
12 graft survival was calculated for mFMSC grafts ( $8\% \pm 4\%$ ) as opposed to mEF grafts ( $32\% \pm 14\%$ )  
13  
14 (figure 2Bc;  $p<0.001$ ).  
15  
16

### 17 18 19 20 ***Quantitative analysis of glial cell responses following mFMSC and mEF grafting***

21  
22 In our preceding studies regarding mMSC and mEF grafting in the CNS of immune competent mice,  
23  
24 we noted that mMSC and mEF grafts became highly infiltrated by microglia (at week 2 post grafting  
25  
26 up to 50-80% of cells within the graft site are microglia) and surrounded by microglia and astrocytes.  
27  
28 From the representative Iba1/eGFP, S100b/eGFP and GFAP/eGFP images provided in figure 2A, it is  
29  
30 clear that mFMSC grafts too become highly infiltrated by microglia and surrounded by both microglia  
31  
32 and astrocytes. As shown in figure 2Bb, microglia comprise respectively  $75\% \pm 6\%$  and  $58\% \pm 3\%$  of  
33  
34 the total number of cells within a mFMSC and mEF graft site, with the ratio of microglia to eGFP+  
35  
36 cells being significantly higher for mFMSC grafts than for mEF grafts (respectively  $2.9 \pm 0.8$  and  
37  
38  $1.5 \pm 0.3$ ,  $p=0.001$ ). The latter can however presumably be explained by the lower degree of cell  
39  
40 survival observed for mFMSC grafts as compared to mEF grafts. For the graft site surrounding, no  
41  
42 difference in density of Iba1+ microglia ( $p=0.205$ ) and S100b+ astrocytes ( $p=0.358$ ) was observed  
43  
44 between mFMSC and mEF grafts (figure 2Bd). Additionally, no difference in the degree of GFAP+  
45  
46 astrogliosis was observed around mFMSC and mEF grafts (figure 2Be,  $p=0.924$ ). Therefore, despite  
47  
48 the lower degree of mFMSC graft survival as compared to mEF grafts, no differences were observed  
49  
50 in both degree and organisation of endogenous glial cell responses.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 ***Quantitative analysis of neo-angiogenesis within mFMSC and mEF grafts***  
5

6 Long-term survival of cellular grafts *in vivo* relies on the ability of the grafted cell type to support neo-  
7 angiogenesis. Although the precise mode of action has not yet been fully unravelled, it is well  
8 recognized that fibroblasts play a major role in physiological and pathological angiogenesis.  
9 Therefore, we additionally determined neo-angiogenesis in mFMSC and mEF grafts. As shown by the  
10 representative CD31/eGFP images in figure 2A and their graphical representation in figure 2Bf, a  
11 significantly lower blood vessel density was observed within mFMSC as compared to mEF cell grafts  
12 (p<0.001). This observation is fully in line with our *in vitro* results regarding the respectively  
13 reduced/increased VEGF production by mFMSC and mEF under inflammatory conditions (figure 1E).  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## DISCUSSION

Fibroblastoid cells of mesenchymal origin are considered as highly attractive candidates for cell grafting experiments in the CNS. Although the main aim in this strategy is not direct cell replacement therapy, fibroblast(-like) cells might exert beneficial effects by means of bystander therapy. For example, exploitation of their immune-modulating, regeneration-inducing and/or anti-apoptotic capacity has been well described in multiple pre-clinical disease models of CNS and peripheral injury (1,5,9,25,27). Additionally, mesenchymal cells are attractive candidates as carriers for therapeutic proteins *in vivo*, a strategy that is extensively investigated at the moment (23,26). Nevertheless, little is currently known about the actual *in vivo* fate of the grafted cells. In our preceding studies, we already described that both mMSC and mEF become surrounded and infiltrated by microglia and surrounded by astrocytes. In this study we observed a similar immune recognition pattern *in vivo* using mFMSC as an extra-embryonic mesenchymal cell population. However, our data do highlight several differences between mEF and mFMSC. First, in contrast to mEF, mFMSC do not display proliferation *in vitro*. Currently, we do not have a valid explanation for this observation, although it remains to be elucidated whether the used culture medium for mFMSC can be further optimised. With regard to this matter, it should be noted here that murine foetal membranes are developmentally organised differently compared to human foetal membranes (11), and therefore might benefit from the use of a different expansion medium (in this study we used expansion medium that has proven effective for hFMSC). Second, for our cultured mFMSC we were unable to demonstrate *in vitro* tri-lineage differentiation, a feature that is also under debate for hFMSC (19). However, as mEF displayed differentiation into adipogenic and osteogenic lineage, we believe our *in vitro* differentiation protocol to be satisfactory. Therefore, murine development may have imposed distinct features to mFMSC and mEF/mMSC, despite all being of mesenchymal origin. Further research will have to address this topic. Of note, a recently published study also attributed distinct immunomodulatory and migratory

1  
2  
3  
4 mechanisms to human mesenchymal cells derived from different tissues (15,20). Third, while mEF  
5 cultures are responsive to LPS/IFN $\gamma$  signalling, mFMSC cultures are unresponsive, at least with  
6 regards to TNF $\alpha$  production. Although further investigation will be needed to determine the presence  
7 and/or absence of Toll-like receptors on both cell populations and their responsiveness to stimuli of the  
8 immune system, the unresponsiveness of mFMSC can potentially be viewed in light of protecting the  
9 embryo against inflammatory signalling during maternal inflammation. However, with regard to the  
10 intrinsic capacity of mFMSC and mEF to suppress TNF $\alpha$  by activated microglia, we did not observe  
11 significant differences between both cell populations. This observation can however be explained by  
12 the fact that most – if not all – cells of mesenchymal origin display this feature *in vitro* (13). Fourth,  
13 despite the absence of a manifest difference in the *in vivo* immune response triggered against mFMSC  
14 or mEF grafts, it was clearly noted that mFMSC display a lower degree of cell graft survival as  
15 compared to mEF grafts. Although further research will be needed, our study indicated differences in  
16 the capacity of mFMSC and mEF to produce VEGF. The ability to support neo-angiogenesis is a  
17 major prerequisite for cell graft survival as – in most cases – cell transplantation is performed without  
18 any structural support. **Unexpectedly**, we first noted that mFMSC produce high levels of VEGF, while  
19 mEF do not. However, upon co-culture of mFMSC with (activated) microglial cells, a reduction in  
20 VEGF secretion was noted. In contrast, mEF are triggered to produce high levels of VEGF upon co-  
21 culture with activated microglial cells. As we have shown in a preceding study that microglia within  
22 MSC grafts display an M1-oriented phenotype (10), we here suggest that the activation status of graft-  
23 infiltrating microglia might trigger different angiogenic responses in different fibroblast-like cell  
24 types, thereby potentially correlating the lower degree of mFMSC graft survival as compared to mEF  
25 graft survival. Our work thus implies that further research using advanced cellular and molecular  
26 analysis tools will have to reveal the complex signalling between mesenchymal cell grafts, microglia,  
27 astrocytes and especially endothelial (progenitor) cells *in vivo*. The latter has also been suggested by *in*  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 *in vitro* observations describing a crosstalk between mesenchymal stromal cells and endothelial  
5  
6 progenitor cells under certain conditions (6,18).  
7  
8

9  
10  
11 Concluding this study, we have compared the behaviour of mFMSC and mEF *in vitro* and *in vivo*  
12  
13 following grafting in the CNS. The presented data indicate significant differences in the ability of both  
14  
15 cell populations to respond to inflammatory stimuli, resulting in differential production of TNF $\alpha$  and  
16  
17 VEGF under normal and inflammatory conditions. Although further investigation is needed, these  
18  
19 apparent differences may lie at the basis of the presence or absence of functional recovery following  
20  
21 grafting of different fibroblastoid cell types in animal models of CNS (and other) injuries. Our data  
22  
23 thus underscore the need for a thorough characterisation of the cell populations used in cell  
24  
25 transplantation studies, as well as the need for comparative cell transplantation studies with similar,  
26  
27 but developmentally different, cell populations. Only the latter will lead to a better understanding of  
28  
29 the beneficial effects observed in many pre-clinical studies that currently face difficulties when being  
30  
31 translated to human clinical applications.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 **Conflict of interest:**  
5

6 The authors confirm that there are no conflicts of interest.  
7  
8  
9

10  
11 **Acknowledgements:**  
12

13 This work was supported by research grants G.0136.11 and G.0130.11 (granted to ZB and PP) of the  
14 Fund for Scientific Research-Flanders (FWO-Vlaanderen, Belgium) and in part by a Methusalem  
15 research grant from the Flemish government (granted to ZB and HG). Nathalie De Vocht and Chloé  
16 Hoornaert hold a PhD-studentship from the FWO-Vlaanderen. Debbie Le Blon holds a PhD-  
17 studentship from the Flemish Institute for Science and Technology (IWT).  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## References

1. Atoui, R.; Chiu, R. C. Concise review: immunomodulatory properties of mesenchymal stem cells in cellular transplantation: update, controversies, and unknowns. *Stem Cells Transl. Med.* 1(3):200-205; 2012.
2. Barry, F. P.; Murphy, J. M. Mesenchymal stem cells: clinical applications and biological characterization. *Int. J. Biochem. Cell Biol.* 36(4):568-584; 2004.
3. Benjamini, Y.; Hochberg, Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. *J. R. Statist. Soc. B.* 57(1):289-300; 1995.
4. Bergwerf, I.; De Vocht, N.; Tambuyzer, B.; Verschuere, J.; Reekmans, K.; Daans, J.; Ibrahim, A.; Van Tendeloo, V.; Chatterjee, S.; Goossens, H.; Jorens, P. G.; Baekelandt, V.; Ysebaert, D.; Van Marck, E.; Berneman, Z. N.; Van der Linden, A.; Ponsaerts, P. Reporter gene-expressing bone marrow-derived stromal cells are immune-tolerated following implantation in the central nervous system of syngeneic immunocompetent mice. *BMC Biotechnol.* 9:1; 2009.
5. Bergwerf, I.; Tambuyzer, B.; De Vocht, N.; Reekmans, K.; Praet, J.; Daans, J.; Chatterjee, S.; Pauwels, P.; Van der Linden, A.; Berneman, Z. N.; Ponsaerts, P. Recognition of cellular implants by the brain's innate immune system. *Immunol. Cell Biol.* 89(4):511-516; 2011.
6. Bidarra, S. J.; Barrias, C. C.; Barbosa, M. A.; Soares, R.; Amedee, J.; Granja, P. L. Phenotypic and proliferative modulation of human mesenchymal stem cells via crosstalk with endothelial cells. *Stem Cell. Res.* 7(3):186-197; 2011.
7. Bieback, K.; Wuchter, P.; Besser, D.; Franke, W.; Becker, M.; Ott, M.; Pacher, M.; Ma, N.; Stamm, C.; Kluter, H.; Muller, A.; Ho, A. D. Mesenchymal stromal cells (MSCs): science and friction. *J. Mol. Med. (Berl).* 90(7):773-782; 2012.
8. Cargnoni, A.; Gibelli, L.; Tosini, A.; Signoroni, P. B.; Nassuato, C.; Arienti, D.; Lombardi, G.; Albertini, A.; Wengler, G. S.; Parolini, O. Transplantation of allogeneic and xenogeneic placenta-derived cells reduces bleomycin-induced lung fibrosis. *Cell Transplant.* 18(4):405-422; 2009.
9. Dailey, T.; Tajiri, N.; Kaneko, Y.; Borlongan, C. V. Regeneration of neuronal cells following cerebral injury. *Front. Neurol. Neurosci.* 32:54-61; 2013.
10. De Vocht, N.; Lin, D.; Praet, J.; Hoornaert, C.; Reekmans, K.; Le Blon, D.; Daans, J.; Pauwels, P.; Goossens, H.; Hens, N.; Berneman, Z.; Van der Linden, A.; Ponsaerts, P. Quantitative and phenotypic analysis of mesenchymal stromal cell graft survival and recognition by microglia and astrocytes in mouse brain. *Immunobiol.* 218(5):696-705; 2013.
11. Dobrova, M. P.; Pereira, P. N.; Deprest, J.; Zwijsen, A. On the origin of amniotic stem cells: of mice and men. *Int. J. Dev. Biol.* 54(5):761-777; 2010.
12. Evangelista, M.; Soncini, M.; Parolini, O. Placenta-derived stem cells: new hope for cell therapy? *Cytotechnol.* 58(1):33-42; 2008.
13. Haniffa, M. A.; Collin, M. P.; Buckley, C. D.; Dazzi, F. Mesenchymal stem cells: the fibroblasts' new clothes? *Haematologica* 94(2):258-263; 2009.
14. Ilancheran, S.; Moodley, Y.; Manuelpillai, U. Human fetal membranes: a source of stem cells for tissue regeneration and repair? *Placenta* 30(1):2-10; 2009.
15. Liu, K. J.; Wang, C. J.; Chang, C. J.; Hu, H. I.; Hsu, P. J.; Wu, Y. C.; Bai, C. H.; Sytwu, H. K.; Yen, B. L. Surface expression of HLA-G is involved in mediating immunomodulatory effects of placenta-derived multipotent cells (PDMCs) towards natural killer lymphocytes. *Cell Transplant.* 20(11-12):1721-1730; 2011.
16. Manuelpillai, U.; Moodley, Y.; Borlongan, C. V.; Parolini, O. Amniotic membrane and amniotic cells: potential therapeutic tools to combat tissue inflammation and fibrosis? *Placenta* 32 Suppl 4:S320-325; 2011.

17. Manuelpillai, U.; Tchongue, J.; Lourensz, D.; Vaghjiani, V.; Samuel, C. S.; Liu, A.; Williams, E. D.; Sievert, W. Transplantation of human amnion epithelial cells reduces hepatic fibrosis in immunocompetent CCl<sub>4</sub>-treated mice. *Cell Transplant.* 19(9):1157-1168; 2010.
18. Oskowitz, A.; McFerrin, H.; Gutschow, M.; Carter, M. L.; Pochampally, R. Serum-deprived human multipotent mesenchymal stromal cells (MSCs) are highly angiogenic. *Stem. Cell? Res.* 6(3):215-225; 2011.
19. Parolini, O.; Alviano, F.; Bergwerf, I.; Boraschi, D.; De Bari, C.; De Waele, P.; Dominici, M.; Evangelista, M.; Falk, W.; Hennerbichler, S.; Hess, D. C.; Lanzoni, G.; Liu, B.; Marongiu, F.; McGuckin, C.; Mohr, S.; Nolli, M. L.; Ofir, R.; Ponsaerts, P.; Romagnoli, L.; Solomon, A.; Soncini, M.; Strom, S.; Surbek, D.; Venkatachalam, S.; Wolbank, S.; Zeisberger, S.; Zeitlin, A.; Zisch, A.; Borlongan, C. V. Toward cell therapy using placenta-derived cells: disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table. *Stem Cells Dev.* 19(2):143-154; 2010.
20. Payne, N. L.; Sun, G.; McDonald, C.; Layton, D.; Moussa, L.; Emerson-Webber, A.; Veron, N.; Siatskas, C.; Herszfeld, D.; Price, J.; Bernard, C. C. Distinct immunomodulatory and migratory mechanisms underpin the therapeutic potential of human mesenchymal stem cells in autoimmune demyelination. *Cell Transplant.* 22(8):1409-1425; 2013.
21. Praet, J.; Reekmans, K.; Lin, D.; De Vocht, N.; Bergwerf, I.; Tambuyzer, B.; Daans, J.; Hens, N.; Goossens, H.; Pauwels, P.; Berneman, Z.; Van der Linden, A.; Ponsaerts, P. Cell type-associated differences in migration, survival, and immunogenicity following grafting in CNS tissue. *Cell Transplant.* 21(9):1867-1881; 2012.
22. Reekmans, K.; De Vocht, N.; Praet, J.; Fransen, E.; Le Blon, D.; Hoornaert, C.; Daans, J.; Goossens, H.; Van der Linden, A.; Berneman, Z.; Ponsaerts, P. Spatiotemporal evolution of early innate immune responses triggered by neural stem cell grafting. *Stem Cell Res. Ther.* 3(6):56; 2012.
23. Reekmans, K.; Praet, J.; Daans, J.; Reumers, V.; Pauwels, P.; Van der Linden, A.; Berneman, Z. N.; Ponsaerts, P. Current challenges for the advancement of neural stem cell biology and transplantation research. *Stem Cell Rev.* 8(1):262-278; 2012.
24. Reekmans, K. P.; Praet, J.; De Vocht, N.; Tambuyzer, B. R.; Bergwerf, I.; Daans, J.; Baekelandt, V.; Vanhoutte, G.; Goossens, H.; Jorens, P. G.; Ysebaert, D. K.; Chatterjee, S.; Pauwels, P.; Van Marck, E.; Berneman, Z. N.; Van der Linden, A.; Ponsaerts, P. Clinical potential of intravenous neural stem cell delivery for treatment of neuroinflammatory disease in mice? *Cell Transplant.* 20(6):851-869; 2011.
25. Ronsyn, M. W.; Berneman, Z. N.; Van Tendeloo, V. F.; Jorens, P. G.; Ponsaerts, P. Can cell therapy heal a spinal cord injury? *Spinal Cord* 46(8):532-539; 2008.
26. Ronsyn, M. W.; Daans, J.; Spaepen, G.; Chatterjee, S.; Vermeulen, K.; D'Haese, P.; Van Tendeloo, V. F.; Van Marck, E.; Ysebaert, D.; Berneman, Z. N.; Jorens, P. G.; Ponsaerts, P. Plasmid-based genetic modification of human bone marrow-derived stromal cells: analysis of cell survival and transgene expression after transplantation in rat spinal cord. *BMC Biotechnol.* 7:90; 2007.
27. Shinozuka, K.; Dailey, T.; Tajiri, N.; Ishikawa, H.; Kim, D. W.; Pabon, M.; Acosta, S.; Kaneko, Y.; Borlongan, C. V. Stem cells for neurovascular repair in stroke. *J. Stem Cell Res. Ther.* 4(4):12912; 2013.
28. Tambuyzer, B. R.; Bergwerf, I.; De Vocht, N.; Reekmans, K.; Daans, J.; Jorens, P. G.; Goossens, H.; Ysebaert, D. K.; Chatterjee, S.; Van Marck, E.; Berneman, Z. N.; Ponsaerts, P. Allogeneic stromal cell implantation in brain tissue leads to robust microglial activation. *Immunol. Cell Biol.* 87(4):267-273; 2009.
29. Yu, S.; Tajiri, N.; Franzese, N.; Franzblau, M.; Bae, E.; Platt, S.; Kaneko, Y.; Borlongan, C. V. Stem cell-like dog placenta cells afford neuroprotection against ischemic stroke model via

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

30. heat shock protein upregulation. PLoS. One 8(9):e76329; 2013.  
Zeger, S. L.; Liang, K. Y.; Albert, P. S. Models for longitudinal data - a generalized estimating equation approach. Biometrics 44(4):1049-1060; 1988.

For Review Only

## Figure legends

### **Figure 1: *In vitro* characterisation of mFMSC and mEF.**

(A) Bright field images of *in vitro* cultured mFMSC (a) and mEF (b). The scale bar indicates 200  $\mu$ m.

Inset images: flow cytometric analysis of eGFP expression. Thin line histogram: FL-1 fluorescence of

control mFMSC (a) and mEF (b). Bold line histogram: eGFP fluorescence of mFMSC-eGFP (a) and

mEF-eGFP (b). Immunophenotypical analysis of mFMSC (c) and mEF (d). Thin line histogram:

unstained control. Bold line histogram: specific antibody staining. Representative images were chosen

from 2 independent immune phenotyping experiments for mFMSC and mEF. (B) *In vitro* growth of

mFMSC(-eGFP) (n=9) and mEF(-eGFP) (n=3) cultures. The counted cell number at plating was set to

1 for data analysis. The values are given as the average  $\pm$  standard deviation. **Results indicate an**

**increase in cell number over time for mEF cultures ( $p < 0.001$ ) and a decrease in cell number over time**

**for mFMSC cultures ( $p < 0.001$ ).** (C) *In vitro* differentiation potential of mFMSC and mEF. Adipogenic

differentiation assay: lipid droplets marked by Oil Red O staining for neutral lipids. Osteogenic

differentiation assay: calcium deposition evidenced by Alizarin Red staining (scale bar = 100  $\mu$ m).

Representative images were chosen from 2 independent differentiation experiments for mFMSC and

mEF. (D) *In vitro* evaluation of immunomodulation properties of mFMSC and mEF. (a) Schematic

overview of the experimental outline. (b) Bar chart shows TNF $\alpha$  secretion by BV2 cells alone, after

stimulation with LPS/IFN $\gamma$  and after co-culture with mFMSC or mEF. TNF $\alpha$  production has been

quantified by ELISA on cell culture supernatants 24 hours after LPS/IFN $\gamma$  stimulation. Presented

results are given as average  $\pm$  standard deviation for 2 independent stimulation experiments for

mFMSC and mEF, with each experiment performed in quadruplicate (for each condition, n=8).

**Results indicate: (i) that BV2 cells produce significant levels of TNF $\alpha$  upon stimulation with**

**LPS/IFN $\gamma$  ( $p < 0.001$ ), (ii) that mFMSC reduce the level of TNF $\alpha$  production by LPS/IFN $\gamma$ -stimulated**

**BV2 cells ( $p < 0.001$ ), (iii) that mEF produce significant levels of TNF $\alpha$  upon stimulation with**

1  
2  
3  
4 LPS/IFN $\gamma$  ( $p < 0.001$ ), and (iv) that despite intrinsic potential to produce TNF $\alpha$ , mEF still reduce the  
5 level of TNF $\alpha$  production by LPS/IFN $\gamma$ -stimulated BV2 cells ( $p = 0.001$ ). (E) *In vitro* VEGF production  
6 by mFMSC and mEF. Bar chart shows VEGF production by mFMSC or mEF alone, after stimulation  
7 with LPS/IFN $\gamma$  in the presence or absence of BV2 cells. VEGF production has been quantified by  
8 ELISA on cell culture supernatants 24 hours after LPS/IFN $\gamma$  stimulation. Presented results are given as  
9 average  $\pm$  standard deviation for 2 independent stimulation experiments for mFMSC and mEF, with  
10 each experiment performed in quadruplicate (for each condition,  $n = 8$ ). Results indicate: (i) that  
11 mFMSC produce significant levels of VEGF ( $p < 0.001$ ), (ii) that both non-activated and LPS/IFN $\gamma$ -  
12 stimulated BV2 cells can suppress VEGF production by mFMSC ( $p < 0.001$  and  $p = 0.004$ ), and (iii) that  
13 mEF display an increased level of VEGF production upon stimulation with LPS/IFN $\gamma$  ( $p < 0.001$ ),  
14 which is further increased in the presence of LPS/IFN $\gamma$ -stimulated BV2 cells ( $p < 0.001$ ).

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33 **Figure 2: Histological analysis of mFMSC-eGFP and mEF-eGFP grafts in the central nervous**  
34 **system of immune competent mice.**

35  
36  
37 (A) Representative immunofluorescent images of the histological analysis of mFMSC-eGFP and  
38 mEF-eGFP grafts. Direct eGFP fluorescence (in green) combined with (from left to right): nuclear  
39 staining with DAPI (in blue), immunofluorescent staining for microglia (Iba1, in red), astrocytes  
40 (S100b, in red), astrogliosis (GFAP, in blue) and blood vessels (CD31, in red) at week 2 post  
41 implantation. Representative images were chosen from multiple stained slides ( $n = 2$  for eGFP/Iba1  
42 and eGFP/S100b/GFAP combinations, and  $n = 1$  for eGFP/CD31 combination) per cell graft analysed  
43 ( $n = 4$  for mFMSC-eGFP grafts and  $n = 5$  for mEF grafts). The scale bars indicate 100  $\mu$ m. (B)  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

(a) Graft site volume in  $\text{mm}^3$ . Significant difference between mFMSC and mEF ( $p < 0.001$ ). (b)

1  
2  
3  
4 Absolute number of Iba1+ microglia (white bars) and eGFP+ cells (black bars) within the graft site.

5  
6 Significant difference between mFMSC and mEF with regard to total cell density ( $p=0.002$ ) and

7  
8 significant difference between mFMSC and mEF with regard to total number of surviving eGFP+

9  
10 cells. (c) Cell graft survival given in %. Significant difference between mFMSC and mEF ( $p<0.001$ ).

11  
12 (d) Density of Iba1+ microglia (white bars) and S100b+ astrocytes (gray bars) within the implant

13  
14 border. (e) Degree of astrogliosis within the implant border (presented as % coverage based on GFAP


15  
16 staining). (f) Density of CD31+ blood vessels within the implant site. Significant difference between

17  
18 mFMSC and mEF ( $p<0.001$ ).


19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Review Only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



160x243mm (300 x 300 DPI)



210x277mm (300 x 300 DPI)